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Most 
 
in vitro
 
 studies show that prenatal administration of cortico-
steroids stimulates the synthesis of surfactant phosphatidylcholine
(PC), but studies in animals are controversial. Whether prenatal
corticosteroids stimulate surfactant PC synthesis in humans has
not been studied. We studied endogenous surfactant PC synthesis
in relation to prenatal corticosteroid treatment in 27 preterm in-
fants with respiratory distress syndrome. Infants received a 24-h
 
infusion of the stable isotope [U-
 
13
 
C]glucose, starting 
 
z
 
 5 h after
birth. We measured 
 
13
 
C-incorporation into palmitic acid in surfac-
tant PC from serial tracheal aspirates and in plasma triglycerides and
phospholipids by isotope-ratio mass spectrometry. Premature in-
fants had received either zero (n 
 
5
 
 11), one (n 
 
5
 
 4), or two doses
(n 
 
5
 
 12) of prenatal betamethasone (12 mg intramuscularly). The
fractional synthesis rate (FSR) of surfactant PC from glucose was
1.7 
 
6
 
 0.3%/d without corticosteroid treatment, 2.9 
 
6
 
 1.4%/d
with one dose of prenatal corticosteroid, and 5.8 
 
6
 
 1.3%/d after
two doses of prenatal corticosteroid. Using multiple regression
analysis, we found that the FSR of surfactant PC increased by
40% (confidence interval: 7 to 82%/d, p 
 
,
 
 0.02) per dose of cor-
ticosteroid and doubled after two doses of corticosteroid. The 
 
13
 
C-
enrichment of plasma triglycerides and phospholipids was not in-
creased by corticosteroid. These data show for the first time that
prenatal corticosteroid treatment stimulates surfactant synthesis
in the preterm infant.
 
After very premature delivery, many infants develop respira-
tory distress syndrome (RDS) caused by primary surfactant
deficiency, among other factors. Prenatal corticosteroid ad-
ministration to women at risk for premature delivery reduces
the incidence and severity of RDS, as well as reducing mortal-
ity in preterm infants (1). Prenatal corticosteroids improve
pulmonary function in preterm animals with RDS by stimulat-
ing structural development (2), inducing antioxidant enzymes
(3), and decreasing vascular permeability (4). Improved pul-
monary function can also result from increased amounts of
surfactant in the alveolar space. In many 
 
in vitro
 
 studies, corti-
costeroids have been found to increase the activity of the en-
zymes needed for the synthesis of surfactant lipids (5–7) and
to increase surfactant protein synthesis (6, 8–10). In 
 
in vitro
 
experiments with lung slices and isolated type II cells, corti-
costeroids have been found to increase the incorporation of
radiolabeled precursors into surfactant PC, reflecting in-
creased PC synthesis (5, 7, 11–13). Despite these strong indica-
tions for corticosteroid stimulation of PC synthesis, most stud-
ies with animals do not show increased surfactant PC pool
sizes or increased precursor incorporation after prenatal corti-
costeroid treatment (2, 4, 14–20); some studies have reported
increased surfactant pool sizes (20–22); and one study found
decreased alveolar surfactant pool sizes after a single dose of
prenatal betamethasone (23). The amount or concentration of
surfactant in the alveolar space does not adequately reflect
surfactant synthesis, because both of these variables depend
on the amount of surfactant secreted into and cleared from the
alveolus. 
In a randomized study of preterm baboons, it was recently
found that surfactant PC synthesis from glucose was stimu-
lated by two doses of prenatal corticosteroids (24). Whether
prenatal corticosteroids stimulate surfactant PC synthesis in
preterm infants with primary surfactant deficiency has not
been studied. We recently reported data on surfactant metab-
olism in six premature infants, using a novel and safe tech-
nique (25). The present clinical study is the first implementa-
tion of our recently developed method. With this technique,
involving the use of stable isotopes, we tested the hypothesis
that prenatal corticosteroids stimulate surfactant synthesis in
critically ill preterm infants with RDS.
 
METHODS
 
Patients and Study Design
 
Consecutive infants requiring mechanical ventilation were studied from
directly after birth. Inclusion criteria were a gestational age 
 
,
 
 32 wk, in-
tubation for RDS as defined clinically and by chest radiography (26),
and written parental informed consent. Exclusion criteria were congen-
ital infection, maternal diabetes, and chromosomal abnormality. Pa-
tients received a constant intravenous infusion of the stable isotope
[U-
 
13
 
C]glucose (Campro Scientific, Veenendaal, The Netherlands) for
24 h at 0.17 mg/kg/min. The start of the study (t 
 
5
 
 0) was defined by
the start of the isotope infusion. This was 5.3 
 
6
 
 0.5 h (mean 
 
6
 
 SEM)
after birth. The total glucose intake was 5.7 mg/kg/min including non-
labeled glucose, and the infants did not receive any lipids during the
first 48 h of the study. Before and during the glucose infusion, 1 ml of
arterial blood was drawn every 6 h for the determination of 
 
13
 
C-enrich-
ment of plasma glucose and of palmitic acid in plasma triglycerides, in
phospholipids, and in the free fatty acid fraction. Exogenous surfactant
(Survanta; Abbott Laboratories, North Chicago, IL) was administered
endotracheally at t 
 
5
 
 0, at a dose of 100 mg/kg phospholipids, if the
mean airway pressure exceeded 7.5 cm H
 
2
 
O, or if the inspiratory oxy-
gen fraction was higher than 0.40. Infants received a second dose of
100 mg/kg phospholipids 6 h later if the foregoing criteria were still
met. The attending neonatologist administered a third dose of surfac-
tant (100 mg/kg), if appropriate, within 20 h after the second dose. 
Tracheal aspirates were obtained every 6 h during the period that
the infant was intubated. Tracheal suctioning was performed during
routine patient care, and did not deviate from the normal clinical pro-
tocol (25). Tracheal aspirates were immediately frozen at 
 
2
 
20
 
8
 
 C until
further processing. No tracheal suctioning was done within 6 h after
 
(
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surfactant administration. Total parenteral nutrition, including lipids,
was started at t 
 
5
 
 48 h. 
Infants were grouped according to the number of doses of prenatal
corticosteroids that their mother received (one dose 
 
5
 
 12 mg dexam-
athasone intramuscularly). When delivery at admission was expected
immediately, corticosteroids were not given (Group 0). When deliv-
ery was not expected immediately, the first dose of corticosteroids
was given (Group 1). A second dose of corticosteroids was given 24 h
after the first dose if delivery had not occurred (Group 2). The study
was approved by the medical ethics committee of the University of
Rotterdam and the university hospital.
 
Surfactant PC Palmitate Isolation
 
The tracheal aspirates were processed as previously described (25). In
short, cells were removed by centrifugation, internal standard was
added, organic extraction was used to isolate surfactant lipids (27),
and surfactant PC was isolated by thin-layer chromatography (TLC)
(28). The PC was derivatized (29) and the fatty acid methyl esters
were stored at 
 
2
 
20
 
8
 
 C. Tracheal aspirates containing visible blood were
not analyzed.
 
Surfactant PC Concentration
 
The fatty acid methyl esters were analyzed with gas chromatography
(GC), and the quantity of each ester was calculated from the internal
standard (30). The concentration of surfactant PC in the epithelial lin-
ing fluid (ELF) was calculated by correction for dilution of the ELF
during endotracheal suctioning with normal saline, as follows: dilution
factor 
 
5
 
 urea in serum/urea in tracheal aspirate (31).
 
Blood Samples
 
Collected blood was directly centrifuged in order to separate cells
from plasma. Through organic solvent extraction, the plasma was di-
vided into a water fraction containing glucose and an organic solvent
fraction containing lipids (32). The glucose was isolated with anion
and cation exchange resins (25), and was derivatized to an aldonitrile
pentacetate derivative (33). From the plasma lipid fraction, triglycer-
ides, phospholipids, and free fatty acids were isolated by TLC, using
Kieselgel plates (Merck, Darmstadt, Germany). The solvent system
contained heptane/diisopropylether/acetic acid 60:40:3 (vol/vol/vol).
The triglycerides, phospholipids, and free fatty acids were derivatized
(29) and the fatty acid methyl esters were stored at 
 
2
 
20
 
8
 
 C.
 
Determination of Enrichment
 
The 
 
13
 
C-enrichment of palmitic acid in surfactant PC, triglycerides,
phospholipids, and free fatty acids, and that of plasma glucose was
measured with GC–combustion interface–isotope-ratio mass spec-
trometry (GC-CI-IRMS) (VG Isotech; Middlewich, Cheshire, UK)
(25, 29). The enrichment is expressed in atom percent excess (APE),
which represents the increase in the percentage of 
 
13
 
C atoms in total
CO
 
2
 
 from the combusted compounds above baseline enrichment (be-
fore isotope infusion). Enrichments were corrected for the contribu-
tion of unlabeled carbon atoms added during derivatization.
 
Calculations
 
Because palmitic acid is by far the most abundant fatty acid in surfac-
tant PC, calculations were performed for this fatty acid only (25). The
first appearance of enrichment was defined as the time delay between
the start of the [U-
 
13
 
C]glucose infusion and the detection of enriched
palmitic acid in surfactant PC. The first appearance of enrichment was
calculated by plotting the regression line for the linear increase in the
enrichment-versus-time curve and extrapolating it to baseline enrich-
ment (25, 34). The fractional synthesis rate (FSR) of surfactant PC is
the percentage of the total surfactant PC pool synthesized from glu-
cose per day. The FSR was calculated by dividing the slope of the lin-
ear increase in 
 
13
 
C-enrichment of PC palmitate by the steady-state
 
13
 
C-enrichment of plasma glucose (25, 34). The half-life of surfactant
PC was calculated by exponential curve fitting of the downslope of
the enrichment-versus-time curve (25).
 
Statistics
 
Data are presented as mean 
 
6
 
 SEM or as median (range). Compari-
sons between the largest groups of 0 (n 
 
5
 
 11) and 2 (n 
 
5
 
 12) doses of
prenatal corticosteroids were made with the Mann–Whitney U test. To
adjust for potential confounding factors in the evaluation of the num-
ber of doses of corticosteroids with regard to enrichment, multiple re-
gression analysis was used. In this analysis the FSR had to be trans-
formed logarithmically in order to obtain normally distributed data.
 
RESULTS
 
Twenty-seven infants were included in the study, 11 in Group
0 (no prenatal corticosteroids), four in Group 1 (one dose of
prenatal corticosteroids), and 12 in Group 2 (two doses of pre-
natal corticosteroids) (Table 1). The patient groups were com-
parable with regard to gestational age, birth weight, and the
fraction of infants who were of normal size or small for gesta-
tional age. The RDS grade and number of days of ventilation
were similar among the study groups (Table 1). The 
 
13
 
C-enrich-
ment of plasma glucose reached a steady state in all infants be-
tween t 
 
5
 
 6 and 24 h, and was similar in all groups (Group 0:
 
TABLE 1
PATIENT CHARACTERISTICS
 
Doses of Prenatal
Corticosteroids
Birth Weight
(
 
g
 
)
Gestational Age
(
 
wk
 
)
RDS Grade
(
 
0–4
 
)
Doses of
Surfactant
(
 
n
 
)
Days of
Ventilation
(
 
n
 
)
None (Group 0) 1,035 (640–2,030) 29.4 (25.9–32.0) 3.5 (1–4) 2.0 (1–3) 5.5 (1.0–51)
One (Group 1) 878 (590–1,800) 26.6 (25.6–31.3) 3.0 (2–3) 2.0 (1–2) 8.5 (5.0–17)
Two (Group 2) 905 (715–1,270) 27.9 (25.6–30.3) 2.5 (0–4) 1.5 (0–2) 6.8 (1.0–39)
p Value, 0 versus 2 doses 0.5 0.3 0.1 0.02 0.8
 
Definition of abbreviation
 
: RDS 
 
5
 
 respiratory distress syndrome.
Figure 1. 13C-enrichment of palmitic acid in surfactant PC. Ventilated
preterm infants received a 24-h [U-13C]glucose infusion as a precursor
for PC palmitate. Preterm infants were exposed to zero, one, or two
doses of prenatal corticosteroids. The increased synthesis of PC after
betamethasone administration is reflected by the increased incorpora-
tion of 13C during the first days of life.
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2.65 
 
6
 
 0.15 APE; Group 1: 2.28 
 
6
 
 0.09 APE; Group 2: 2.43 
 
6
 
0.14 APE). Infants in Group 2 required a significantly lower
number of doses of surfactant than those in Group 0. (1.5 [0 to 2]
and 2.0 [1 to 3], respectively, p 
 
5
 
 0.02). In total, 468 tracheal
aspirates were analyzed. The 
 
13
 
C-enrichment of palmitic acid
in surfactant PC in the three groups is shown in Figure 1. The
figure shows an increased 
 
13
 
C-enrichment in the corticosteroid-
treated groups as compared with Group 0, The kinetic parameters
were calculated from these curves and are shown in Table 2.
The first appearance of 
 
13
 
C-enrichment and the half-life of
surfactant PC were similar in the three study groups. There
was a trend toward earlier maximal enrichment in Group 2
as compared with Group 0 (59.4 
 
6
 
 4.0 h and 76.9 
 
6
 
 7.8 h,
p 
 
5
 
 0.07). The FSR of palmitic acid in surfactant PC from glu-
cose was significantly increased by the administration of pre-
natal corticosteroids (Figure 2). Univariate analysis of data for
Group 0 and Group 2, showed that surfactant synthesis was
significantly increased by corticosteroids (1.7 
 
6
 
 0.3%/d versus
5.9 
 
6
 
 1.3%/d, p 
 
5
 
 0.0002). Because exogenous surfactant di-
lutes the labeled surfactant PC derived from endogenous syn-
thesis in the type II pneumocyte, we corrected for the number
of doses of surfactant administered, using multiple regression
analysis. This analysis also allowed correction for the effect of
gestational age. The mean FSR increased linearly on a loga-
rithmic scale, with an increase of 40% (95% confidence inter-
val: 7 to 82%, p 
 
,
 
 0.02) per dose of corticosteroids adminis-
tered prenatally. This corresponds approximately to a twofold
(1.4 
 
3
 
 1.4) increase after two doses of prenatal corticosteroids
as compared with no prenatal treatment.
The liver can use infused [U-
 
13
 
C]glucose for lipogenesis,
which results in labeled plasma lipids (25). The type II pneu-
mocyte can use palmitic acid from plasma triglycerides, phos-
pholipids, and free fatty acids for surfactant PC synthesis.
Therefore, an increased labeling of surfactant PC after prenatal
administration of corticosteroids could in theory result from in-
creased 
 
13
 
C-enrichment of plasma lipids, from synthesis by the
liver after administration of corticosteroids, with subsequent
uptake by lung. To study this possibility, we measured the 
 
13
 
C-
enrichment of palmitic acid in plasma triglycerides and phos-
pholipids, and in the free fatty acid fraction. The palmitic acid in
triglycerides and phospholipids became 
 
13
 
C-enriched within 6 h
after the start of the [U-
 
13
 
C]glucose infusion (Figures 3A and
3B). The enrichment of free palmitic acid was too low (much
lower than that of surfactant PC palmitate) to be measured ac-
curately, and was therefore measured only in several patients
(data not shown). There was no statistically significant differ-
ence between the groups with regard to 
 
13
 
C-enrichment of
palmitic acid in plasma triglycerides and phospholipids. These
data show that the increased enrichment of surfactant PC palm-
itate after prenatal administration of corticosteroids was due to
increased endogenous synthesis of surfactant PC, and was not a
reflection of plasma lipid enrichment. The surfactant PC con-
centration at birth (before surfactant administration) was 2.4
(0.4 to 14.3 mg/ml ELF) in Group 0, 2.9 (1.7 to 4.2) mg/ml ELF
in Group 1, and 8.1 (0.9 to 37.5) mg/ml ELF in Group 2. Al-
though the surfactant PC concentration tended to be higher in
Group 2, this was not statistically significant, probably because
of the small number of infants studied. The concentration of
surfactant PC was measured in only 16 of the 27 patients be-
cause some infants had already received exogenous surfactant
as therapy before informed consent was obtained for the study.
 
DISCUSSION
 
This study describes for the first time in humans the relation
between the exposure to prenatal corticosteroids and 
 
de novo
 
surfactant PC synthesis. The clinical study is the first imple-
mentation of our recently developed method for evaluating
surfactant metabolism with stable isotopes. Preterm infants
received [U-
 
13
 
C]glucose as a precursor for the synthesis of
palmitic acid in surfactant PC. We found significantly in-
creased surfactant PC synthesis from glucose, with an increase
of 40% per dose of prenatal corticosteroids. This implies that
administration of two doses of corticosteroids to the mother at
risk of preterm labor, as is generally accepted clinically (35), dou-
bles the production of surfactant PC from glucose in the pre-
term infant. This finding shows that stimulated general lung matu-
ration is accompanied by increased surfactant PC production.
These findings are in accord with those in many 
 
in vitro
 
studies that show induction of enzymes for surfactant synthe-
 
TABLE 2
KINETICS OF SURFACTANT PHOSPHATIDYLCHOLINE IN
RELATION TO PRENATAL CORTICOSTEROID TREATMENT
 
Doses of Prenatal
Corticosteroid
Time of First Appearance
of Enrichment
(
 
h
 
)
Time of Maximal
Enrichment
(
 
h
 
)
Half-Life
(
 
h
 
)
Fractional Synthesis
Rate
(
 
%/d
 
)
Concentration of PC
(
 
mg/ml ELF
 
)
None (Group 0) 18.7 
 
6
 
 2.8 76.9 
 
6
 
 7.8 [7] 98.8 
 
6
 
 8.3 [5] 1.7 
 
6
 
 0.3 2.4 (0.4–14.3) [5]
One (Group 1) 21.3 
 
6
 
 2.2 76.8 
 
6
 
 7.6 [4] 105 
 
6
 
 10.9 [3] 2.9 
 
6
 
 1.4 2.9 (1.7–4.2) [2]
Two (Group 2) 17.4 
 
6
 
 3.0 59.4 
 
6
 
 4.0 [8] 86.0 
 
6
 
 9.9 [8] 5.9 
 
6
 
 1.3 8.1 (0.9–37.5) [9]
p Value, 0 versus 2 doses 0.26 0.07 0.34 0.0002 0.19
 
Definition of abbreviations
 
: ELF 
 
5
 
 epithelial lining fluid; PC 
 
5
 
 phosphatidylcholine.
Twenty-seven preterm infants received either zero, one, or two doses of prenatal corticosteroid. The fractional synthesis rate and time of
first appearance of enrichment were measured in all infants. Time of maximal enrichment, half-life, and phosphatidycholine concentration
were measured in the number of infants, [n], given in brackets.
Figure 2. FSR of surfactant PC. Infants received a 24-h [U-13C]glucose
infusion, and the 13C-enrichment of surfactant PC palmitate was mea-
sured throughout the period of ventilation. The difference between
zero and two doses was significant (p , 0.001).
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sis and increased precursor incorporation after prenatal ad-
ministration of corticosteroids (11, 12). Glucose incorporation
into surfactant PC in organotypic cultures of type II cells is in-
creased by betamethasone (12). In a study by Kessler and col-
leagues of premature baboons, a 72-h treatment with prenatal
dexamethasone did not increase incorporation of radioactive
palmitate into lung lipids, but shifted the incorporation to di-
saturated PC in lung lavage fluid 3 h after birth (20). We re-
cently found that in very preterm baboons that received exog-
enous surfactant and were ventlilated for 6 d, surfactant PC
synthesis from glucose approximately doubled after two pre-
natal doses of corticosteroids, which is comparable with the
findings in the present study (24).
Data on surfactant pool sizes in animal studies as an indica-
tion of surfactant synthesis 
 
in vivo
 
 are conflicting; some stud-
ies have found increased pool sizes (20–22), but most studies
have not found an increased surfactant pool in the lung after
corticosteroid administration (2, 4, 14–19). We found that the
concentration of surfactant PC in ELF tended to increase after
two doses of corticosteroids at birth (Table 2). The concentra-
tion of PC was measured in only 16 of our 27 patients because
some infants had already received exogenous surfactant be-
fore informed consent was obtained for their enrollment. In a
study by Kari and coworkers of human preterm infants, prenatal
dexamethasone had no significant effect on the surfactant con-
centration in ELF (36). Ballard and associates and Ikegami
and colleagues did not find an increased total-lung saturated
PC pool size at birth in preterm lambs when corticosteroids
were administered from 2 to 4 d before preterm delivery.
However, when corticosteroids were administered 1 wk be-
fore delivery, the total lung saturated PC pool at birth had in-
 
creased significantly (16, 21). The discrepancies between in-
creased surfactant synthesis and nonsignificantly increased
surfactant pool sizes or concentrations in ours and other studies
can be explained by the low surfactant synthesis rate relative
to the pool size.
The foregoing hypothesis is supported by the other kinetic
parameters for surfactant PC generation found in our study
(Table 2). The long delay between the start of the stable iso-
tope infusion and the first 
 
13
 
C-enrichment of surfactant PC
palmitate shows that the synthesis of palmitate, intracellular
processing, and secretion of surfactant into the alveolar space
is a slow process. The delay between the start of the isotope
infusion and the time of maximal enrichment was long in all
groups. The time to maximal enrichment and half-life of sur-
factant PC tended to be shorter in Group 2, which is compati-
ble with stimulated surfactant metabolism. The long half-lives
of 
 
13
 
C-enrichment show that endogenously synthesized surfac-
tant remains in the lungs for many days and is diluted slowly
by newly synthesized, unlabeled surfactant. The half-lives for
phosphatidylglycerol (
 
z
 
 105 h) and sphingomyelin (
 
z
 
 97 h) in
preterm infants treated with Survanta were comparable to our
data (37). The half-life of phosphatidylglycerol was 
 
z
 
 30 h in
preterm infants treated with surfactant extracted from human
amniotic fluid (38). In the newborn rabbit, the half-life of sur-
factant PC was 
 
z
 
 57 h when labeled with palmitic acid and
 
z
 
 136 h when labeled with choline (39). Increased clearance
of labeled surfactant from the lung shortens the half-lives of its
components, and greater recycling of components of surfac-
tant prolongs their half-lives. These variables were not mea-
sured in our study, and can affect findings in such studies. The
type of surfactant studied and the label used also influence
half-life measurements (37, 39).
In the present study we measured the synthesis of palmitic
acid in surfactant PC only from glucose. Besides glucose, the
type II cell has several other sources for the synthesis of sur-
factant PC, including palmitic acid, intracellular glycogen, lac-
tate, and ketone bodies (40). Glucose is, however, an impor-
tant substrate for the fatty acids of surfactant PC (41–43),
certainly in relative fatty acid deficiency, such as in our infants,
in whom intravenous feeding with lipids was begun 48 h after
the start of the isotope infusion. The type II cell can use palm-
itic acid from the plasma free fatty acid fraction, from plasma
triglycerides, and probably from phospholipids for the synthe-
sis of surfactant PC (42). The lung fibroblast accumulates trig-
lycerides and transfers these lipids to the type II pneumocyte,
and this process is stimulated 
 
in vitro
 
 in rat lung by glucocorti-
coids (44). An increased 
 
13
 
C-enrichment of surfactant PC
could therefore be a reflection of increased 
 
13
 
C-enrichment of
plasma lipids due to stimulated lipogenesis in the liver after
prenatal administration of steroids. We measured the 
 
13
 
C-en-
richment of palmitic acid in plasma free fatty acids, triglycer-
ides, and phospholipids in all three of our study groups. As
shown in Figures 3A and 3B, the 
 
13
 
C-enrichment of triglycer-
ides and phospholipids did not change after prenatal steroid
administration, and could not have led to increased 
 
13
 
C-incor-
poration into surfactant in the corticosteroid-treated groups.
The 
 
13
 
C-enrichment of palmitic acid in the free fatty acid frac-
tion was too low to be measured accurately (much lower than
that of surfactant PC), and was therefore measured only in
some patients (data not shown). Thus, the increased incorpo-
ration of 
 
13
 
C from glucose into surfactant PC found in Groups
1 and 2 does not reflect a 
 
13
 
C-enrichment of plasma lipids, but
rather reflects increased surfactant phospholipid synthesis
from glucose. The increased FSR of surfactant PC reflects the
principle that prenatal steroids increase surfactant phospho-
lipid production in the preterm infant, but the extent of the to-
Figure 3. 13C-enrichment of plasma triglycerides (A) and of plasma
phospholipids (B). After a 24-h [U-13C]glucose infusion, the 13C-enrich-
ment of palmitic acid was measured in these plasma lipids. The 13C-enrich-
ment of triglycerides and phospholipids in plasma was not increased
by prenatal corticosteroid administration.
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tal absolute increase is unclear, since the contribution of the
other precursors was unknown.
The total surfactant pool and the pools of the metabolic in-
termediates are unknown, but are influenced by treatment
with large amounts of exogenous surfactant. We corrected for
the potential confounding effects of the number of doses of
exogenous surfactant through multiple regression analysis. As
a result of the way in which we enrolled our patients, the dif-
ferent groups could have been subject to different durations of
prenatal stress. The impact of such prenatal stress was, how-
ever, unknown, which constitutes a limitation of our study.
Nevertheless, it is ethically impossible to perform a study such
as ours with preterm infants in a randomized fashion, since ad-
ministration of prenatal corticosteroids is an established ther-
apy for improving outcome for premature infants. However,
in a randomized study of premature baboons, we found a com-
parable increase in surfactant PC synthesis after treatment
with prenatal corticosteroids (24).
In summary, this study shows for the first time that prenatal
corticosteroid treatment increases surfactant PC production from
the important precursor glucose in the preterm infant with severe
RDS. The data show that endogenous surfactant metabolism is a
slow process, and that stimulation of surfactant synthesis by
steroids probably increases alveolar surfactant pool sizes only
after many days. Therefore, the increased surfactant synthesis
found after the generally recommended corticosteroid treatment
of pretrem infants (35), probably plays only a minor role in the
reduced incidence of RDS and improved outcome of this patient
population. The accelerated development of the surfactant system
is part of the enhanced integrated development of the lung.
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